Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells $1,827,105.28 in Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Karen Anderson sold 64,768 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $28.21, for a total transaction of $1,827,105.28. Following the completion of the transaction, the insider owned 62,085 shares in the company, valued at $1,751,417.85. The trade was a 51.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $27.06 on Friday. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The firm has a market cap of $3.95 billion, a P/E ratio of -14.79 and a beta of 1.55. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $9.60 and a 1-year high of $30.58. The firm has a 50-day moving average of $25.26 and a 200-day moving average of $24.64.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on CNTA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. B. Riley Financial lifted their price target on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a report on Monday, December 1st. Wolfe Research started coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, February 24th. They set an “outperform” rating and a $40.00 price objective on the stock. Finally, Oppenheimer upped their price objective on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $39.80.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC raised its stake in shares of Centessa Pharmaceuticals by 116.2% in the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after acquiring an additional 5,808,080 shares during the period. EcoR1 Capital LLC grew its holdings in Centessa Pharmaceuticals by 466.4% during the 4th quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock valued at $77,906,000 after purchasing an additional 2,565,000 shares during the last quarter. Braidwell LP bought a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $54,730,000. Federated Hermes Inc. purchased a new stake in Centessa Pharmaceuticals in the 3rd quarter worth about $42,429,000. Finally, Maverick Capital Ltd. bought a new stake in Centessa Pharmaceuticals in the fourth quarter worth about $41,110,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.